

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 13, 2026



Illumina, Inc.

(Exact name of registrant as specified in its charter)

001-35406

(Commission File Number)

Delaware

(State or other jurisdiction of incorporation)

33-0804655

(I.R.S. Employer Identification No.)

5200 Illumina Way, San Diego, CA 92122

(Address of principal executive offices) (Zip code)

(858) 202-4500

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value	ILMN	The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act.

TABLE OF CONTENTS

[Item 2.02 Results of Operations and Financial Condition](#)

[Item 9.01 Financial Statements and Exhibits](#)

[SIGNATURES](#)

[Exhibit Index](#)

[Table of Contents](#)

Item 2.02 Results of Operations and Financial Condition.

On January 13, 2026, in advance of a public webcast presentation at the J.P. Morgan Healthcare Conference in San Francisco, California, Illumina, Inc. (the "Company") issued a press release regarding the Company's unaudited preliminary financial results for the fourth quarter and fiscal year ended December 28, 2025. The webcast is accessible through the Investor Relations section of the Company's website and will remain available for at least 30 days following. Pursuant to General Instruction F to Form 8-K, a copy of the press release is attached hereto as [Exhibit 99.1](#) and is incorporated into this Item 2.02 by this reference.

The information furnished pursuant to this Item 2.02 (including [Exhibit 99.1](#)) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.

[Table of Contents](#)

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

[99.1](#) Press release dated January 13, 2026, announcing Illumina, Inc.'s preliminary unaudited financial results for the fourth quarter and fiscal year ended December 28, 2025

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

[Table of Contents](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 13, 2026

ILLUMINA, INC.

By: /s/ ANKUR DHINGRA

Name: Ankur Dhingra

Title: Chief Financial Officer

[Table of Contents](#)

Exhibit Index

Exhibit Number	Description
99.1	Press release dated January 13, 2026, announcing Illumina, Inc.'s preliminary unaudited financial results for the fourth quarter and fiscal year ended December 28, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)



Investors:
Conor McNamara
+1.858.291.6421
ir@illumina.com

Media:
Christine Douglass
pr@illumina.com

Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025

San Diego, January 13, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025 ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). The webcast can be accessed through Illumina's website at investor.illumina.com.

Preliminary fourth quarter 2025 results:

- Revenue of approximately \$1.155 billion, up 5% from Q4 2024 (up 4% on a constant currency basis)
- Ex-China revenue of approximately \$1.100 billion, up 7% from Q4 2024 (and on a constant currency basis)
- GAAP diluted EPS of \$2.14 to \$2.17 and non-GAAP diluted EPS of \$1.27 to \$1.30

Preliminary fiscal year 2025 results:

- Revenue of approximately \$4.34 billion, flat compared to 2024 (and on a constant currency basis)
- Ex-China revenue of approximately \$4.10 billion, up 2% from 2024 (and on a constant currency basis)
- GAAP diluted EPS of \$5.42 to \$5.45 and non-GAAP diluted EPS of \$4.76 to \$4.79

As previously announced, the company expects to report its full fourth quarter and fiscal year 2025 results following the close of market on Thursday, February 5, 2026. The unaudited results in this press release are preliminary and subject to the completion of accounting and annual audit procedures and are therefore subject to adjustment.

Statement regarding use of non-GAAP financial measures

The company reports non-GAAP results for diluted earnings per share, net income, gross margin, operating expenses, including research and development expense, selling general and administrative expense, legal contingency and settlement, and goodwill and intangible impairment, operating income, operating margin, gross profit, other income (expense), tax provision, constant currency revenue and growth, and free cash flow (on a consolidated and, as applicable, segment basis) in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The company's financial measures under GAAP include substantial charges such as amortization of acquired intangible assets among others that are listed in the reconciliations of GAAP and non-GAAP financial measures included in this press release, as well as the effects of currency translation. Management has excluded the effects of these items in non-GAAP measures to assist investors in analyzing and assessing past and future operating performance. Non-GAAP net income, diluted earnings per share and operating margin are key components of the financial metrics utilized by the company's board of directors to measure, in part, management's performance and determine significant elements of management's compensation.

The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.

The company provides forward-looking guidance on a non-GAAP basis, including on a constant currency basis for revenue and revenue growth rates. The company is unable to provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures because it is unable to predict with reasonable certainty the impact of items such as acquisition-related expenses, fair value adjustments to contingent consideration, gains and losses from strategic investments, potential future asset impairments, restructuring activities, the ultimate outcome of pending litigation, and currency exchange rate fluctuations without unreasonable effort. These items are uncertain, inherently difficult to predict, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, the company is unable to address the significance of the unavailable information, which could be material to future results.

Use of forward-looking statements

This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) changes in the rate of growth in the markets we serve, including the proteomics market; (ii) the volume, timing and mix of customer orders among our products and services; (iii) our ability to adjust our operating expenses to align with our revenue expectations; (iv) the completion of the proposed acquisition of SomaLogic, Inc. and certain other assets (the SomaLogic Business) from Standard BioTools Inc. on the anticipated terms and timeline, or at all, including the ability of the parties to obtain required regulatory approvals – such as under the Hart-Scott-Rodino Act in the United States or from government authorities that may have or assert jurisdiction outside the United States – and to satisfy other closing conditions; (v) our ability to successfully integrate the SomaLogic Business into our existing operations and the SomaLogic Business' technology and products into our portfolio; (vi) our ability to successfully manage partner and customer relationships in the proteomics market; (vii) uncertainty regarding the impact of our inclusion on the "unreliable entities list" by regulatory authorities in China; (viii) uncertainty regarding tariffs imposed or threatened by the U.S. government and its trading partners, and other possible tariffs or trade protection measures and our efforts to mitigate the impact of such tariffs; (ix) our ability to manufacture robust instrumentation and consumables, including the SomaLogic Business' products; (x) the success of products and services competitive with our own; (xi) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; (xii) the impact of recently launched or pre-announced products and services on existing products and services; (xiii) our ability to modify our business strategies to accomplish our desired operational goals; (xiv) our ability to realize the anticipated benefits from prior or future actions to streamline and improve our R&D processes, reduce our operating expenses and maximize our revenue growth; (xv) our ability to further develop and commercialize our instruments, consumables, and products; (xvi) to deploy new products, services, and applications, and to expand the markets for our technology platforms; (xvii) the risk of additional litigation arising against us in connection with the GRAIL acquisition; (xviii) our ability to obtain approval by third-party payors to reimburse patients for our products; (xix) our ability to obtain regulatory clearance for our products from government agencies; (xx) our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business; (xxi) uncertainty, or adverse economic and business conditions, including as a result of slowing or uncertain economic growth or armed conflict; (xxii) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments and (xxiii) legislative, regulatory and economic developments, together with other factors detailed in our filings with the Securities and Exchange Commission, including recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Illumina, Inc.
Preliminary Results of Operations - Non-GAAP
(unaudited)

Our performance and financial results are subject to risks and uncertainties, and actual results could differ materially from preliminary results set forth below. Some of the factors that could affect our financial results are included from time to time in the public reports filed with the Securities and Exchange Commission (SEC), including [Form 10-K](#) for the fiscal year ended December 29, 2024, filed with the SEC on February 12, 2025, [Form 10-Q](#) for the fiscal quarter ended March 30, 2025, [Form 10-Q](#) for the fiscal quarter ended June 29, 2025, and [Form 10-Q](#) for the fiscal quarter ended September 28, 2025. We assume no obligation to update any forward-looking statements or information.

The preliminary unaudited information included in the tables below is approximate and subject to change. As previously announced, we will report our fourth quarter and full year fiscal 2025 results on February 5, 2026. Revenue information for fiscal year 2024, including growth rates, is for our Core Illumina segment.

PRELIMINARY CONSTANT CURRENCY REVENUE:

<i>Dollars in millions</i>	Three Months Ended			Year Ended		
	December 28, 2025	December 29, 2024	% Change	December 28, 2025	December 29, 2024	% Change
Preliminary revenue	\$ 1,155	\$ 1,104	5 %	\$ 4,339	\$ 4,332	— %
Less: Hedge effect	(4)	5		(5)	15	
Revenue, excluding hedge effect	1,159	1,099		4,344	4,317	
Less: Exchange rate effect	15	—		20	—	
Constant currency revenue (a)	\$ 1,144	\$ 1,099	4 %	\$ 4,324	\$ 4,317	— %

PRELIMINARY CONSTANT CURRENCY REVENUE EXCLUDING GREATER CHINA:

<i>Dollars in millions</i>	Three Months Ended			Year Ended		
	December 28, 2025	December 29, 2024	% Change	December 28, 2025	December 29, 2024	% Change
Preliminary revenue	\$ 1,100	\$ 1,024	7 %	\$ 4,096	\$ 4,024	2 %
Less: Hedge effect	(4)	3		(7)	10	
Revenue, excluding hedge effect	1,104	1,021		4,103	4,014	
Less: Exchange rate effect	15	—		21	—	
Constant currency revenue (a)	\$ 1,089	\$ 1,021	7 %	\$ 4,082	\$ 4,014	2 %

RECONCILIATION BETWEEN PRELIMINARY GAAP AND NON-GAAP DILUTED EARNINGS PER SHARE:

	Fourth Quarter 2025	Fiscal Year 2025
Preliminary GAAP diluted earnings per share	\$2.14 to \$2.17	\$5.42 to \$5.45
Acquisition-related costs (c)	0.24	0.53
Transformational initiatives (d)	0.06	0.39
Intangible asset impairment	—	0.15
Strategic investment gain, net (e)	(1.24)	(2.13)
Other (f)	0.12	0.14
Income tax provision (g)	(0.05)	0.26
Preliminary non-GAAP diluted earnings per share (b)	\$1.27 to \$1.30	\$4.76 to \$4.79

- (a) Constant currency revenue growth, which is a non-GAAP financial measure, is calculated using comparative prior period foreign exchange rates to translate current period revenue, net of the effects of hedges.
- (b) Non-GAAP diluted earnings per share excludes the effects of the pro forma adjustments detailed above. Non-GAAP diluted earnings per share is a key component of the financial metrics utilized by the company's board of directors to measure, in part, management's performance and determine significant elements of management's compensation. Management has excluded the effects of these items to assist investors in analyzing and assessing past and future operating performance.
- (c) Amounts consist primarily of amortization of intangible assets, legal and other expenses related to the GRAIL and pending SomaLogic acquisitions, and fair value adjustments on our contingent consideration liabilities.
- (d) Amounts consist primarily of employee severance costs related to restructuring activities and costs related to implementation efforts to upgrade our ERP system.
- (e) Amounts consist primarily of mark-to-market adjustments and impairments from strategic investments.
- (f) Amounts consist primarily of a donation to the Illumina foundation, costs related to board membership changes, and legal contingency accruals.
- (g) Amounts represent the aggregate of the difference between book and tax accounting related to stock-based compensation cost, a one-time valuation allowance adjustment against deferred tax assets associated with certain U.S. foreign tax credits as a result of the U.S. tax legislation that was signed on July 4, 2025, and the tax impact related to the non-GAAP adjustments.